Nimbus Therapeutics tests a dual inflammation and repair thesis with SIK2 inhibitors

Nimbus Therapeutics unveils SIK2 inhibitor data at ECCO 2026. Explore what this means for oral IBD therapies and mucosal healing strategies.

Nimbus Therapeutics unveils SIK2 inhibitor data at ECCO 2026. Explore what this means for oral IBD therapies and mucosal healing strategies.